Protocols
2 protocol(s) meet the specified criteria
Drug: DARATUMUMAB
Protocol No.TitleStatus
INCB01158-206“A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma”Open
KCP-330-017STOMPKCP-330-017 STOMP A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple MyelomaOpen